Therapeutic Area
2022
Poster
Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab
International Gynecologic Cancer Society (IGCS) Annual Global Meeting
2022
PresentationGlucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel
European Society for Medical Oncology (ESMO) Congress
2022
PosterPhase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer
European Society for Medical Oncology (ESMO) Congress
2022
PosterRelacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study
European Society for Medical Oncology (ESMO) Congress
2022
PresentationOverall survival data from a 3-arm randomized phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer
American Society of Clinical Oncology (ASCO) Annual Meeting
2022
PosterA study of relacorilant in combination with nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma (mPDAC)
American Society of Clinical Oncology (ASCO) Annual Meeting
2022